At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 311 enrolled
Drug / intervention
Mapracorat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
In Brief
A Phase 3 clinical trial evaluating Mapracorat and Vehicle for Cataract. Completed, enrolled 311 participants across 1 site.
Detailed Summary
The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionJun 2011
Study CompletionAug 2011
TodayJul 2026
First PostedOct 28, 2010
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.7 years ago
Interventions
Mapracoratdrug
Instill study medication into study eye per dosing instructions for 14 days
Vehicledrug
Instill study medication into the study eye per dosing instructions for 14 days